These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 17293705

  • 1. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW, Lee JG, Lee BJ, Kim YH.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [Abstract] [Full Text] [Related]

  • 2. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ, Lee JG, Kim YH.
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [Abstract] [Full Text] [Related]

  • 3. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1810-5. PubMed ID: 18727948
    [Abstract] [Full Text] [Related]

  • 4. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY.
    J Clin Psychiatry; 2006 Dec 12; 67(12):1912-9. PubMed ID: 17194269
    [Abstract] [Full Text] [Related]

  • 5. Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
    Schubert MH, Young KA, Hicks PB.
    Biol Psychiatry; 2006 Sep 15; 60(6):530-3. PubMed ID: 16806095
    [Abstract] [Full Text] [Related]

  • 6. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.
    Fagerlund B, Søholm B, Fink-Jensen A, Lublin H, Glenthøj BY.
    Clin Neuropharmacol; 2007 Sep 15; 30(1):3-12. PubMed ID: 17272964
    [Abstract] [Full Text] [Related]

  • 7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.
    Encephale; 2008 Dec 15; 34(6):557-62. PubMed ID: 19081451
    [Abstract] [Full Text] [Related]

  • 8. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D, Olver JS, Maruff P, Norman TR.
    Hum Psychopharmacol; 2009 Aug 15; 24(6):437-46. PubMed ID: 19637398
    [Abstract] [Full Text] [Related]

  • 9. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP, Khan A.
    Schizophr Res; 2011 Feb 15; 125(2-3):267-77. PubMed ID: 20850275
    [Abstract] [Full Text] [Related]

  • 10. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S.
    Hum Psychopharmacol; 2009 Apr 15; 24(3):233-8. PubMed ID: 19330802
    [Abstract] [Full Text] [Related]

  • 11. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW.
    Clin Neuropharmacol; 2009 Apr 15; 32(2):69-74. PubMed ID: 18978489
    [Abstract] [Full Text] [Related]

  • 12. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S, Stip E, Poulin J, Melun JP, Godbout R, Guillem F, Cohen H.
    Curr Med Res Opin; 2007 Mar 15; 23(3):575-83. PubMed ID: 17355738
    [Abstract] [Full Text] [Related]

  • 13. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH, Wang GH, Wang XP, Chen RY, Wang HL, Yang MH, Huo YX, Mei HB.
    Hum Psychopharmacol; 2008 Aug 15; 23(6):465-70. PubMed ID: 18536066
    [Abstract] [Full Text] [Related]

  • 14. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD.
    J Clin Psychopharmacol; 2006 Oct 15; 26(5):495-9. PubMed ID: 16974191
    [Abstract] [Full Text] [Related]

  • 15. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A, Ritsner MS.
    Clin Neuropharmacol; 2008 Oct 15; 31(4):204-20. PubMed ID: 18670244
    [Abstract] [Full Text] [Related]

  • 16. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.
    Hum Psychopharmacol; 2009 Oct 15; 24(7):565-73. PubMed ID: 19790174
    [Abstract] [Full Text] [Related]

  • 17. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
    Kumari V, Aasen I, ffytche D, Williams SC, Sharma T.
    Neuroimage; 2006 Jan 15; 29(2):545-56. PubMed ID: 16181792
    [Abstract] [Full Text] [Related]

  • 18. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D, Hutchinson M, Larsen JP.
    Int J Geriatr Psychiatry; 2003 Oct 15; 18(10):937-41. PubMed ID: 14533126
    [Abstract] [Full Text] [Related]

  • 19. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL, Goldberg TE.
    Biol Psychiatry; 2004 May 15; 55(10):1013-22. PubMed ID: 15121486
    [Abstract] [Full Text] [Related]

  • 20. Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.
    Kim J, Chung SY, Park S, Park JH, Byun S, Hwang M, Oh DS, Choi H, Kim MY, Bu YC, Doré S, Whang WW, Kim H.
    Pharmacol Biochem Behav; 2008 Oct 15; 90(4):517-24. PubMed ID: 18550156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.